There are 2789 resources available
326P - National multicentre retrospective study on metastatic breast cancer patients to characterize long responder under eribulin: LORELINE study
Presenter: Marie Ange Mouret Reynier
Session: ePoster Display
327P - Predictors of progression-free survival in patients with metastatic breast cancer receiving palbociclib with letrozole
Presenter: Roya Behrouzi
Session: ePoster Display
328TiP - Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2–positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09
Presenter: Sara Tolaney
Session: ePoster Display
211P - Genetic and immunologic characteristics in Chinese breast patients with different HER2 mutation types
Presenter: Hui Cao
Session: ePoster Display
212P - HER2-low breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatment
Presenter: Federica Miglietta
Session: ePoster Display
213P - Predictive markers of cardiotoxicity associated with breast cancer treatment
Presenter: Ines Nogueira Costa
Session: ePoster Display
331TiP - HER2CLIMB-04: Phase II trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases
Presenter: Lisa Carey
Session: ePoster Display
216P - Prognostic role of Ki67 cutoff and mPEPI score for neoadjuvant ‘chemotherapy’ in locally advanced HER2-negative ‘luminal’ breast cancer
Presenter: Mutlu Dogan
Session: ePoster Display
217P - The impact of obesity on the survival outcomes of women with breast cancer that achieve pathological complete response
Presenter: Mariana Roman-Zamudio
Session: ePoster Display
254P - Impact of palbociclib-dose reduction on survival: A retrospective cohort study
Presenter: Maria Luisa Romero Lagures
Session: ePoster Display